Supporting information

mARC1 is the main contributor to metabolic reduction of *N*-hydroxyurea

Cathrin Klopp[1,2†], Xiaomei Zhang[3†], Morgan K Campbell[3], David Kvaskoff[4], Michel A Struwe[1,2], Curtis R Warren[3], Besnik Bajrami[4], Axel J Scheidig[1], Amanda K Jones[3] and Bernd Clement[2*]

[1] Zoological Institute − Structural Biology, Kiel University, 24118 Kiel, Germany
[2] Pharmaceutical Institute − Medicinal Chemistry, Kiel University, 24118 Kiel, Germany
[3] Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut 06877; Department of Cardiometabolic Disease Research
[4] Boehringer Ingelheim Pharma GmbH & Co., 88400 Biberach an der Riss, Germany; Department of Drug Discovery Sciences, Discovery Science Technologies (DK, BB)

*Authors to whom correspondence should be addressed:
Email: bclement@pharmazie.uni-kiel.de

Supplementary Figure S1. Hepatic mRNA abundance of Mtarc2 in mice treated with either GalNAc-siMtarc1 or genetically modified to remove Mtarc1. Panel A: Quantification of mARC2 protein in mouse liver. Panel B: Representative immunoblot bands, Panel C: Ratio of hepatic mARC2 protein to vinculin quantified by immunoblotting.

S1